18:48 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Cell culture and mouse studies suggest an ANXA5-targeting, single-chain variable fragment (scFv)-based fusion protein could help treat stroke. The protein consists of an scFv derived from a mouse IgM antibody targeting ANXA5, which is...
02:10 , Feb 11, 2017 |  BioCentury  |  Product Development

Form(ulation) follows function

A clinical study of two formulations of marketed drug Linzess linaclotide supports Ironwood Pharmaceuticals Inc.’s hypothesis that pain in irritable bowel syndrome with constipation is not due to constipation alone, but also to hypersensitive nerves...
21:05 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Colonic-release linaclotide: Ph IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 532 adult patients with IBS-C showed that once-daily 300 µg oral colonic-release-1 formulation of linaclotide (CR1) for 12 weeks led to a greater proportion of...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Colonic-release linaclotide: Phase IIb started

Ironwood and Allergan began a double-blind, double-dummy, placebo-controlled Phase IIb trial to compare 2 oral colonic-release formulations of linaclotide ( CR1 and CR2) once daily for 12 weeks vs. 290 ug oral linaclotide in...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

T Cell Sciences, Novartis Pharma AG deal

Novartis obtained options to license TCEL's TP10 soluble complement receptor 1 (SCR-1) and the gene for SCR-1 for xenotransplantation and allotransplantation. Under the two-year agreement, Novartis could license TP10 exclusively for transplant with worldwide...
07:00 , Sep 24, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Clusterin...
07:00 , Apr 10, 2008 |  BC Innovations  |  Targets & Mechanisms

Staph: The NOse Have It

A paper published in Science sheds light on why Staphylococcus aureus so successfully colonizes nasal passages and points to a new target, lactate dehydrogenase, for blocking this pathogen before it can cause systemic infection.1 But...
08:00 , Jan 8, 2007 |  BC Week In Review  |  Company News

Elusys, Pfizer deal

The companies partnered to develop infectious disease therapeutics using Elusys' Heteropolymer (HP) Antibody technology, which chemically links together two antibodies. The deal includes Elusys' ETI-211 to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. ETI-211 is...
02:02 , Jan 5, 2007 |  BC Extra  |  Company News

Elusys, Pfizer infectious disease deal

Elusys (Pine Brook, N.J.) and PFE partnered to develop infectious disease therapeutics using Elusys' Heteropolymer (HP) Antibody technology. The deal includes ETI-211 to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. ETI-211 is a preclinical heteropolymer antibody...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Clinical News

Elusys preclinical data

Mice pre-treated with ETI-211 survived an initial and second lethal challenge with S. aureus without additional treatment, while all control mice died. Also, after the first S. aureus challenge, kidney, liver and spleens were free...